Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1.

Guo L, Sun X, Hao Z, Huang J, Han X, You Y, Li Y, Shen M, Ozawa T, Kishi H, Muraguchi A, Jin A.

J Cancer. 2017 Aug 2;8(13):2542-2553. doi: 10.7150/jca.19918. eCollection 2017.

2.

TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis.

Singh HD, Otano I, Rombouts K, Singh KP, Peppa D, Gill US, Böttcher K, Kennedy PTF, Oben J, Pinzani M, Walczak H, Fusai G, Rosenberg WMC, Maini MK.

Sci Rep. 2017 Jul 17;7(1):5514. doi: 10.1038/s41598-017-05845-5.

3.

PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux.

Nazim UM, Moon JH, Lee YJ, Seol JW, Park SY.

Oncotarget. 2017 Apr 18;8(16):26819-26831. doi: 10.18632/oncotarget.15819.

4.

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.

Yuan X, Kho D, Xu J, Gajan A, Wu K, Wu GS.

Oncotarget. 2017 Mar 28;8(13):21626-21638. doi: 10.18632/oncotarget.15451.

5.

The role of TRAIL in fatigue induced by repeated stress from radiotherapy.

Feng LR, Suy S, Collins SP, Saligan LN.

J Psychiatr Res. 2017 Aug;91:130-138. doi: 10.1016/j.jpsychires.2017.03.012. Epub 2017 Mar 20.

PMID:
28343068
6.

TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.

Piao X, Ozawa T, Hamana H, Shitaoka K, Jin A, Kishi H, Muraguchi A.

Oncoimmunology. 2016 May 4;5(5):e1131380. doi: 10.1080/2162402X.2015.1131380. eCollection 2016 May.

7.

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Prostate Cancer Cells after Treatment with Xanthohumol-A Natural Compound Present in Humulus lupulus L.

Kłósek M, Mertas A, Król W, Jaworska D, Szymszal J, Szliszka E.

Int J Mol Sci. 2016 Jun 22;17(6). pii: E837. doi: 10.3390/ijms17060837.

8.

Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease.

Bernardi S, Bossi F, Toffoli B, Fabris B.

Biomed Res Int. 2016;2016:1752854. doi: 10.1155/2016/1752854. Epub 2016 Apr 21. Review.

9.

Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment.

Liguori M, Buracchi C, Pasqualini F, Bergomas F, Pesce S, Sironi M, Grizzi F, Mantovani A, Belgiovine C, Allavena P.

Oncotarget. 2016 Jul 5;7(27):41662-41676. doi: 10.18632/oncotarget.9340.

10.

Onto better TRAILs for cancer treatment.

de Miguel D, Lemke J, Anel A, Walczak H, Martinez-Lostao L.

Cell Death Differ. 2016 May;23(5):733-47. doi: 10.1038/cdd.2015.174. Epub 2016 Mar 4. Review.

11.

Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Brincks EL, Kucaba TA, James BR, Murphy KA, Schwertfeger KL, Sangwan V, Banerjee S, Saluja AK, Griffith TS.

FEBS J. 2015 Dec;282(24):4747-4765. doi: 10.1111/febs.13532. Epub 2015 Oct 18.

12.

Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Amarante-Mendes GP, Griffith TS.

Pharmacol Ther. 2015 Nov;155:117-31. doi: 10.1016/j.pharmthera.2015.09.001. Epub 2015 Sep 5. Review.

13.

TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.

Mohr A, Yu R, Zwacka RM.

BMC Cancer. 2015 Jul 3;15:494. doi: 10.1186/s12885-015-1508-2.

14.

Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage.

Ko H, Jeong MH, Jeon H, Sung GJ, So Y, Kim I, Son J, Lee SW, Yoon HG, Choi KC.

Oncotarget. 2015 Apr 30;6(12):9970-84.

15.

TRAIL modulates the immune system and protects against the development of diabetes.

Bossi F, Bernardi S, Zauli G, Secchiero P, Fabris B.

J Immunol Res. 2015;2015:680749. doi: 10.1155/2015/680749. Epub 2015 Feb 18. Review.

16.

Identification of death receptors DR4 and DR5 in HTB-12 astrocytoma cell lines and determination of TRAIL sensitivity.

Riddick E, Evans S, Rousch J, Gwebu E, Banerjee HN.

J Solid Tumors. 2013 Dec 1;3(6):20-26.

17.

Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2.

Bertsch U, Röder C, Kalthoff H, Trauzold A.

Cell Death Dis. 2014 Aug 28;5:e1390. doi: 10.1038/cddis.2014.351. Review.

18.

DAPK2 is a novel modulator of TRAIL-induced apoptosis.

Schlegel CR, Fonseca AV, Stöcker S, Georgiou ML, Misterek MB, Munro CE, Carmo CR, Seckl MJ, Costa-Pereira AP.

Cell Death Differ. 2014 Nov;21(11):1780-91. doi: 10.1038/cdd.2014.93. Epub 2014 Jul 11.

19.

Chrysin, apigenin and acacetin inhibit tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) on activated RAW264.7 macrophages.

Warat M, Szliszka E, Korzonek-Szlacheta I, Król W, Czuba ZP.

Int J Mol Sci. 2014 Jun 27;15(7):11510-22. doi: 10.3390/ijms150711510.

20.

Getting TRAIL back on track for cancer therapy.

Lemke J, von Karstedt S, Zinngrebe J, Walczak H.

Cell Death Differ. 2014 Sep;21(9):1350-64. doi: 10.1038/cdd.2014.81. Epub 2014 Jun 20. Review.

Supplemental Content

Support Center